Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Zohra Zenasni, Kimberley Goldsmith, R. Hamish McAllister‐Williams, David Keßler et al.
Citations
12 citations
Journal
The Lancet Psychiatry
Topics
Treatment of Major Depression
Field-Weighted Citation Impact (FWCI)
16.73
article
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Zohra Zenasni, Kimberley Goldsmith, R. Hamish McAllister‐Williams, David Keßler, Jess Kerr‐Gaffney, Helena Tee, Nahel Yaziji, Álvaro Barrera, Allan H. Young, R. Taylor, Alessandro Colasanti, John Geddes, Lindsey Marwood, Huajie Jin, Anthony J. Cleare
article en
12 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet PsychiatryVol. 12(4)
Institutions
King's College London (GB), South London and Maudsley NHS Foundation Trust (GB), University of Bristol (GB), University of Oxford (GB)
Funders
National Institute for Health and Care Research, NIHR Maudsley Biomedical Research Centre
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK — Zohra Zenasni, Kimberley Goldsmith, et al. · The Lancet Psychiatry (2025) | TGRS Research Map | TGRS